Home » Archive

News

News, Syndication, Xconomy »

J&J Prostate Cancer Trial Shouldn’t Have Been Stopped Early

Posted by sandiegobiotech June 3rd, 2012 .
No Comments

One of the more anticipated clinical trials at this year’s American Society of Clinical Oncology (ASCO) meeting was for Johnson & Johnson’s abiraterone (Zytiga) in prostate cancer patients. This…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

New San Diego VC Firm Emerges as ‘The Moneyball of Venture Capital’

Posted by sandiegobiotech June 1st, 2012 .
No Comments

[Corrected 6/5/12, 10:05 pm. See below.] Here’s some big news for San Diego’s innovation economy: There’s a new venture capital firm in town—and its investment methodology represents a fundamentally…

[[Click headline to continue reading.]]

More...

Marketwire, News, Syndication »

Quidel to Present at Upcoming Conferences

Posted by Mary Canady May 31st, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – May 31, 2012) – Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions and cellular-based virology assays, announced today that it will present at the following upcoming conferences:

More...

Marketwire, News, Syndication »

Genelux Corporation Announces Treatment of First Patient in Phase I/II Clinical Trial of GL-ONC1 in Advanced Peritoneal Cavity Cancers

Posted by Mary Canady May 31st, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – May 31, 2012) – Genelux Corporation, a privately-held clinical-stage biopharmaceutical company focused on development and commercialization of best-in-class, vaccinia-virus-based oncolytic viral therapies and companion d…

More...

Drug Development, News, Syndication, Xconomy »

SD Biotech Roundup: Wireless Sensor Prize, Zogenix, Sangart, & More

Posted by sandiegobiotech May 31st, 2012 .
No Comments

The X Prize Foundation’s Peter Diamandis came to San Diego to announce the formation of a new incentive prize competition, while a variety of companies disclosed new funding deals. It’s all part of…

[[Click headline to continue reading.]]

More...

Marketwire, News, Syndication »

La Jolla Pharmaceutical Announces Issuance of U.S. Patent Covering Modified Pectin Compositions

Posted by Mary Canady May 31st, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – May 31, 2012) – La Jolla Pharmaceutical Company (OTCQB: LJPC) (PINKSHEETS: LJPC) (the “Company” and “La Jolla”) announced today that the United States Patent and Trademark Office (USPTO) has issued patent number 8,187,642…

More...

Marketwire, News, Syndication »

NuVasive to Participate in Investor Events in June 2012

Posted by Mary Canady May 30th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – May 30, 2012) – NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that the Company will participate in seve…

More...

Marketwire, News, Syndication »

Genelux Corporation Announces Phase I Data Presentation at 2012 ASCO Annual Meeting of GL-ONC1, Its Oncolytic Virus Lead Product Candidate

Posted by Mary Canady May 30th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – May 30, 2012) – Genelux Corporation, a privately held, clinical-stage biopharmaceutical company focused on development and commercialization of best-in-class, vaccinia-virus-based oncolytic viral therapies and companion …

More...

Marketwire, News, Syndication »

Ardea Biosciences Earns Milestone From Bayer HealthCare

Posted by Mary Canady May 30th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – May 30, 2012) – Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced that it has earned a $7.5 million milestone from Bayer HealthCare (Bayer) under the terms of their April 2009 global license agreement to develop and…

More...

Marketwire, News, Syndication »

Cytori Obtains Celution(R) Approval in Russia; To Launch Product Line for Plastic Surgery and Select Soft Tissue Therapies

Posted by Mary Canady May 30th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – May 30, 2012) – Cytori Therapeutics (NASDAQ: CYTX) has obtained approval to sell the Celution® 800 System in Russia for various medical uses. These clinical uses are based on those in the current European CE Mark, and i…

More...